|
Search concepts
|
|
Selected filters
|
- 1 - 50 out of 2,180 results
Search results
-
Which Are the Best Tyrosine Kinase Inhibitors for Newly Diagnosed Chronic Myelogenous Leukemia?
Hughes, T. (Speaker)
30 May 2025 → 3 Jun 2025Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations
-
Novartis Launch Meeting: 'Leading the CML Revolution’
Hughes, T. (Invited speaker)
10 Jun 2025Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations
-
'Embarking on a new journey with Scemblix’ Meeting
Hughes, T. (Speaker)
23 Apr 2025Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations
-
Characterization & Efficacy of Tern-701 in pre-clinical models of Chronic Myeloid Leukemia.
Hughes, T. (Invited speaker)
12 Jun 2025 → 15 Jun 2025Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations
-
New discoveries that will shape future therapies in Chronic Myeloid Leukemia
Hughes, T. (Speaker)
2 Mar 2025 → 29 Mar 2025Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations
-
Debate 1 – CML - Asciminib first line?
Hughes, T. (Invited speaker)
7 Mar 2025 → 9 Mar 2025Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations
-
'CML Elevate Clinic' Event
Hughes, T. (Invited speaker)
29 Apr 2025 → 30 Apr 2025Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations
-
CML Connect Meeting with Chang Gung Memorial Hospital Lankou - Novartis Taiwan
Hughes, T. (Speaker)
24 Apr 2025Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations
-
26th Annual ESH-iCMLF International Conference on CML – Biology and Therapy
Eadie, L. (Participant)
27 Sept 2024 → 29 Sept 2024Activity: Other
-
New Directions in Leukaemia Research (NDLR)
Eadie, L. (Participant)
4 Mar 2024 → 6 Mar 2024Activity: Other
-
Zero Childhood Cancer National Symposium
Eadie, L. (Participant)
8 May 2024 → 9 May 2024Activity: Other
-
-
-
Trans-Tasman Radiation Oncology Group - TROG Cancer Research (External organisation)
Le, H. (Chair)
2024 → …Activity: Membership › Membership of committee
-
Metabolic vulnerabilities of myeloid neoplasm and autoimmune disease.
Hiwase, D. (Speaker)
15 Oct 2024 → 17 Oct 2024Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks
-
New Directions in Leukaemia Research
Thomas, D. (Organiser)
4 Mar 2024 → 6 Mar 2024Activity: Participating in or organising an event › Organising a conference
-
Efficacy of asciminib against ABL-rearrangement of Ph-like Acute Lymphoblastic Leukaemia is dependent on the presence of the SH3 domain.
Lagonik, E. (Speaker)
28 Oct 2024Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks
-
Tyrosine kinase inhibitor-responsive chronic myeloid leukaemia is associated with reduced OXPHOS capacity and mtDNA mutations likely contribute to this.
Pagani, I. (Speaker)
15 May 2024 → 17 May 2024Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations
-
ESH - iCMLf 26th Annual John Goldman Conference on Chronic Myeloid Leukemia
Hughes, T. (Organiser)
27 Sept 2024 → 29 Sept 2024Activity: Participating in or organising an event › Organising a conference
-
ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results.
Hughes, T. (Invited speaker)
31 May 2024 → 4 Jun 2024Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations
-
Scientific Exchange: The Disconnect Between Basic and Clinical Research
White, D. (Speaker)
2 Sept 2024Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations
-
Transcriptomic analysis reveals the intricacies of Ph+ ALL: Examining gene expression patterns and deletions in relation to patient prognosis.
White, D. (Speaker)
27 Sept 2024 → 29 Sept 2024Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations
-
ALL-IMMUNE Study Update
White, D. (Keynote speaker)
13 Dec 2024Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks
-
New Directions in Leukaemia Research
White, D. (Participant)
4 Mar 2024 → 6 Mar 2024Activity: Participating in or organising an event › Organising a conference
-
ALL-IMMUNE Study Update
White, D. (Keynote speaker)
10 Dec 2024Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks
-
-
New Directions in Leukaemia Research (NDLR)
Eadie, L. (Participant)
4 Mar 2024 → 6 Mar 2024Activity: Other
-
Royal Australian and New Zealand College of Radiologists (External organisation)
Le, H. (Chair)
Jan 2024Activity: Membership › Membership of committee
-
New Directions in Leukaemia Research (NDLR)
Eadie, L. (Participant)
4 Mar 2024 → 6 Mar 2024Activity: Other
-
The 5th Australian Cancer and Metabolism Meeting (ACMM 2024)
Thomas, D. (Organiser) & Butler, L. (Organiser)
15 Oct 2024 → 17 Oct 2024Activity: Participating in or organising an event › Organising a conference
-
When Frontline Therapy Fails
Yeung, D. (Invited speaker)
17 Oct 2024 → 18 Oct 2024Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks
-
CML Beyond Chronic Phase
Shanmuganathan, N. (Invited speaker)
17 Oct 2024 → 18 Oct 2024Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks
-
New Directions in Leukaemia Research
Thomas, D. (Participant)
4 Mar 2024 → 6 Mar 2024Activity: Participating in or organising an event › Organising a conference
-
Australian CML Association, CMLa (External organisation)
Pagani, I. (Chair)
1 Mar 2024Activity: Membership › Membership of network
-
ESH - iCMLf 26th Annual John Goldman Conference on Chronic Myeloid Leukemia
Hughes, T. (Chair)
27 Sept 2024 → 29 Sept 2024Activity: Participating in or organising an event › Participation in conference
-
CML Opinion Leaders Training COLT 2024
Yeung, D. (Organiser) & Hughes, T. (Organiser)
17 Oct 2024 → 18 Oct 2024Activity: Participating in or organising an event › Organising a workshop, seminar, course
-
Clinical Spotlight Presentation - Chronic Myeloid Leukaemia: Next Challenges
Hughes, T. (Speaker)
4 Mar 2024 → 5 Mar 2024Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations
-
ALL-IMMUNE Study Update
White, D. (Keynote speaker)
9 Sept 2024Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks
-
Ph+ and Ph-like ALL: New Insights
White, D. (Invited speaker)
17 Oct 2024 → 18 Oct 2024Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks
-
SAHMRI Precision Cancer Medicine Theme Seminar Series
Eadie, L. (Participant)
10 Apr 2024Activity: Other
-
Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) Scientific Meeting
Eadie, L. (Participant)
1 Aug 2024 → 3 Aug 2024Activity: Other
-
New Directions in Leukaemia Research (NDLR)
Eadie, L. (Participant)
4 Mar 2024 → 6 Mar 2024Activity: Other
-
Cancer Institute New South Wales Translational Cancer Research Centre (External organisation)
Skelton, K. (Member)
1 Apr 2024Activity: Membership › Membership of committee
-
New Directions in Leukaemia Research (NDLR)
Eadie, L. (Participant)
4 Mar 2024 → 6 Mar 2024Activity: Other
-
New Directions in Leukaemia Research (NDLR)
Eadie, L. (Speaker)
4 Mar 2024 → 6 Mar 2024Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks
-
26th Annual ESH-iCMLF International Conference on CML – Biology and Therapy
Eadie, L. (Participant)
27 Sept 2024 → 29 Sept 2024Activity: Other
-
New Directions in Leukaemia Research (Event)
Eadie, L. (Chair)
Aug 2024 → …Activity: Membership › Membership of committee
-
New Directions in Leukaemia Research (NDLR)
Eadie, L. (Participant)
4 Mar 2024 → 6 Mar 2024Activity: Other
-
Gut Dysbiosis may adversely impact treatment responses with TKIs in ABL-rearranged high-risk B-ALL
Page, E. (Speaker)
29 Oct 2024Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks
-
Mesenchymal stromal cells from patients with therapy-related myeloid neoplasms exhibit a unique metabolic phenotype with defective adipocyte differentiation.
Kutyna, M. (Speaker)
15 May 2024 → 17 May 2024Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks